# TAF for HIV-HBV With Renal Dysfunction

> **NCT03115736** · PHASE2 · COMPLETED · sponsor: **Insel Gruppe AG, University Hospital Bern** · enrollment: 24 (actual)

## Conditions studied

- HIV and Hepatitis B Coinfection

## Interventions

- **DRUG:** Tenofovir Alafenamide

## Key facts

- **NCT ID:** NCT03115736
- **Lead sponsor:** Insel Gruppe AG, University Hospital Bern
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-23
- **Primary completion:** 2019-12-05
- **Final completion:** 2019-12-05
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2020-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03115736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03115736, "TAF for HIV-HBV With Renal Dysfunction". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03115736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*